INTRODUCTION {#sec1}
============

The use of medical gasses has been recently described as an emerging exotic strategy in the exercise physiology and sports medicine community \[[@cit0001]\], with a few unconventional medical gasses (such as NO, Xe, O~3~) put forward as performance-enhancing agents. Among others, molecular hydrogen (H~2~) appears as an innovative compound that might be applicable among athletes. Usually administered in the form of a dietary supplement, either as hydrogen-rich water or hydrogen-producing tablets, H~2~ appears to positively affect exercise capacity in both animal studies \[[@cit0002]--[@cit0004]\] and human trials \[[@cit0005]--[@cit0008]\]. This might be due to its antioxidant and anti-inflammatory properties \[[@cit0009]\] that perhaps reduce exercise-induced inflammation and oxidative stress or through alteration of anabolic hormones production by signal modulation \[[@cit0010],[@cit0011]\]. For instance, Aoki and co-workers \[[@cit0005]\] reported that hydration with 1.5 L/day of hydrogen-rich water (0.92--1.02 mM of hydrogen) significantly reduced blood lactate levels and improved exercise-induced decline of muscle function in male soccer players. Buffering capacity of hydrogen-rich water (1.1 mM) during exercise-induced acidosis has also been demonstrated after both continuous \[[@cit0006]\] and progressive running-to-exhaustion exercise \[[@cit0007]\]. In addition, two weeks of hydrogen-rich water intake (2 L per day, 0.45 mM of free hydrogen) helped to maintain peak power output in repetitive sprints to exhaustion over 30 minutes in male cyclists \[[@cit0008]\]. Although the above preliminary studies provided initial evidence about the performance-enhancing capacity of hydrogen-rich water, it remains an open question whether the favourable effects originate from H~2~ itself or perhaps from magnesium, a conventional source of hydrogen in hydrogen-rich water. Specifically, the apparent buffering capacity of hydrogen-rich water might be due to various pH buffers (e.g. bicarbonate, metallic magnesium) found in liquid hydrogen products used previously \[[@cit0006],[@cit0007]\] rather than to H~2~ gas, which is known not to influence pH. Applying pure hydrogen gas, instead of magnesium-based hydrogen formulations, might, therefore, help to better reveal the authentic ergogenic potential of H~2~. Moreover, using inhalation as a parenteral route of H~2~ administration could emphasize the systemic action of hydrogen, including the possible impact on insulin and ghrelin secretion \[[@cit0010]\]. Drinking hydrogen-rich water appears to alter plasma glucose and insulin levels, an effect likely mediated by enhanced expression of fibroblast growth factor 21 (FGF21), a metabolic hormone that improves insulin sensitivity and glucose clearance \[[@cit0010]\]. The possible augmented insulin response driven by hydrogen inhalation might promote energy utilization and performance during exercise \[[@cit0012]\], thus fostering H~2~ as an insulin secretion stimulator in an athletic environment. Furthermore, recent evidence suggests that H~2~ has therapeutic value for diseases that involve inflammation \[[@cit0013],[@cit0014]\], thus raising the possibility of its use in the athletic environment by counterbalancing biomarkers of exercise-induced inflammation and damage (e.g. creatine kinase, myoglobin, ferritin, C-reactive protein). In this randomized controlled preliminary trial, we evaluated the effects of 7-day H~2~ inhalation on exercise performance outcomes and serum hormonal and inflammation profiles in a cohort of young active men and women. We hypothesized that gaseous H~2~ would improve cardiorespiratory and muscular performance, and stimulate insulin secretion, along with attenuation of the inflammatory response. This appears to be the first clinical study where H~2~ inhalation was used for athletic performance.
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ANOVA

:   Analysis of variance
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CI

:   Confidence interval
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CRP

:   C-reactive protein
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ESR

:   Erythrocyte sedimentation rate
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FGF21

:   Fibroblast growth factor 21
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H~2~

:   Molecular hydrogen

```{=html}
<!-- -->
```

IGF-1

:   Insulin-like growth factor 1

```{=html}
<!-- -->
```

MVIS

:   Maximal voluntary isometric strength

```{=html}
<!-- -->
```

VO~2max~

:   Maximal oxygen uptake

MATERIALS AND METHODS {#sec2}
=====================

Participants {#sec2.1}
------------

Twenty healthy, physically active young volunteers (age 22.9 ± 1.5 years; body mass index 23.4 ± 2.5 kg/m^2^; 10 women and 10 men) signed informed consent to voluntarily participate in this randomized, double-blind, placebo-controlled, crossover pilot trial, with all procedures approved by the local Institutional Review Board at the University of Novi Sad in accordance with the Declaration of Helsinki. All participants had no history of H~2~ supplementation (or other performance-enhancing dietary supplements or drugs) within the 4 weeks before the study commenced, and no acute or chronic disorders and diseases, as evaluated by the pre-participation health check. Participants were asked to maintain their usual diets and physical activity levels during the study.

Experimental intervention {#sec2.2}
-------------------------

All participants were allocated to receive either gaseous hydrogen (4%) or placebo (room air) by 20-min once-per-day inhalation for 7 days, with a wash-out period of 7 days to prevent the residual effects of interventions across study periods. The concentration of H~2~ used and the duration of an inhalational session (20 min) were chosen as a method that gave a favourable effect in a previous human study \[[@cit0015]\]. Previous studies suggested that continuous inhalation of H~2~ gas requires \~ 10 min to reach equilibrium in the tissue and blood \[[@cit0016]\]. Gaseous hydrogen was provided via a gas mask by biological gas supplying apparatus (MIZ Company Ltd, Kanagawa, Japan), with the H~2~ flow rate approximately constant (\~ 45 mL/min) and diluted by ambient air. Day-to-day H~2~ inhalation was supervised by the study investigators throughout the trial. Placebo gas was identical in appearance to hydrogen. The inhalation was administered at the same time of day (08:00--09:00), \~ 60 min before breakfast, with all participants receiving the intervention simultaneously using multiple machines. The primary treatment outcome was the change in running time-to-exhaustion in the incremental test (see below) from baseline to day 7. Additionally, assessment of other exercise performance endpoints and clinical chemistry biomarkers was performed at baseline and at 7 days after each intervention ([Figure 1](#f0001){ref-type="fig"}).

![Study protocol. Vertical arrows indicate sampling intervals for primary and secondary outcomes.](JBS-36-88756-g001){#f0001}

Study design {#sec2.3}
------------

The study was conducted in the FSPE Applied Bioenergetics Laboratory at the University of Novi Sad from February 2018 to April 2018, with the trial registered at ClinicalTrials.gov (ID NCT03846141). Laboratory assessments were carried out between 08:00 and 12:00 after an overnight fast and no exhaustive exercise over the previous 24 h. Before testing exercise performance outcomes, participants first provided a blood sample at rest from a median cubital vein into an evacuated test tube while seated. The venous blood was immediately centrifuged within the next 10 min at 3000 *g*, with serum separated and analyzed for ghrelin and insulin-like growth factor 1 (IGF-1) using commercial ELISA kits on an automated analyzer (ChemWell 2910, AWARENESS Technology Inc., Palm City, FL). Insulin and ferritin were analyzed using chemiluminescence immunoassays (ADVIA Centaur XP, Siemens Healthcare GmbH, Erlangen, Germany). Myoglobin was analyzed with solid-phase enzyme immunoassay (AIA-360, Tosoh Bioscience, San Francisco, CA), while serum creatine kinase (CK) and C-reactive protein (CRP) were measured by standard enzymatic methods with an automatic analyzer (Hitachi 912, Tokyo, Japan). Erythrocyte sedimentation rate (ESR) was measured with the reference Westergren technique. Blood lactates were measured by the enzymatic-colorimetric method (Accu-Trend, Hoffmann-La Roche Ltd., Basel, Switzerland). After blood chemistry analyses, participants performed a series of different exercise tests. First, maximal voluntary isometric strength (MVIS) of forearm muscles was evaluated with a hydraulic hand dynamometer (Jamar J00105, Lafayette Instrument Company, Lafayette, IN), and MVIS of torso and leg muscles with a Back-Leg-Chest dynamometer (Baseline 12-0403, Fabrication Enterprises Inc., White Plains, NY). Second, muscular endurance in the upper body was assessed through the gender-specific YMCA Bench Press Test \[[@cit0017]\]. Finally, cardiorespiratory endurance was evaluated by a maximal incremental running test on an institutional treadmill (3-min warm-up walk at 6 km/h followed by running at 8 km/h with a progressive workload increment rate of 1.5 km/h every 60 s until exhaustion). Gas exchange data were collected throughout the test using a breath-by-breath metabolic system (Quark CPET, COSMED, Rome, Italy). The test was finished when participants were too physically tired to continue running, and additional criteria for the maximal test were met (e.g. rise in oxygen uptake satisfied a plateau representing less than 2 mL/kg/min to the next level, respiratory exchange ratio ≥ 1.10 and peak heart rate ≥ 95% of age-predicted maximal heart rate). Participants were also instructed to report on adverse effects of H~2~ intervention through an open-ended questionnaire for self-assessment of side effects during the study. All participants were familiarized with testing procedures and were assessed on the same day with the tests performed in the same order.

Statistical analyses {#sec2.4}
--------------------

The appropriate sample size (*n* = 20) was calculated using power analysis (effect size 0.3, alpha error probability 0.05, power 0.80) for the primary treatment outcome (G-Power 3, Heinrich Heine University Düsseldorf, Germany). Two-way mixed model analysis of variance (ANOVA) with repeated measures was used to establish whether any significant differences existed between participants' responses over time of intervention (0 vs. 7 days). When non-homogeneous variances were identified, values were compared using Friedman's 2-way ANOVA by ranks. Identification and removal of outliers were conducted according to the interquartile range method. The significance level was set at *P* ≤ 0.05.

RESULTS {#sec3}
=======

All participants completed the study, with no men or women reporting any adverse events of molecular hydrogen or placebo inhalation. No significant differences were found in most biomarkers' responses between two interventions (*P* \> 0.05), except for serum IGF-1, CRP, and ferritin ([Table 1](#t0001){ref-type="table"}). Hydrogen inhalation resulted in a notable drop in serum IGF-1 for 48.2 ng/mL at follow-up (95% confidence interval \[CI\]: from -186.7 to 89.3), while IGF-1 levels were elevated by 59.3 ng/mL after placebo intervention (95% CI; from -110.7 to 229.5). Baseline CRP levels were decreased by 1.0 mg/L (95% CI; 0.6--1.4) and by 0.7 mg/L (95% CI; 0.3--1.2) after hydrogen and placebo inhalation at 7-day follow up, respectively. Hydrogen also induced a more powerful drop in serum ferritin at follow-up, as compared to placebo (6.4 μg/L *vs*. 5.6 μg/L; *P* ≤ 0.05). Breathing H~2~ was superior to placebo to increase peak running velocity during a maximal incremental running test (by up to 4.2%), also to attenuate a drop in MVIS of torso muscles at 7-day follow-up ([Figure 2](#f0002){ref-type="fig"}). No inter-group differences were observed in terms of handgrip and leg MVIS, muscular endurance during repetitive bench press exercise, or running time-to-exhaustion and maximal oxygen consumption. Individual changes in the primary outcome (running time-to-exhaustion) between trials are presented in [Figure 3](#f0003){ref-type="fig"}, with 12 out of 20 participants (60%) having performed better (or less inferior) after H~2~ inhalation. Nevertheless, an effect size analysis for the primary outcome measure change revealed a small effect size for time vs. intervention interaction (95% CI; from 71 to 183 s after H~2~ intervention, and from 66 to 174 s after placebo intervention, η^2^ = 0.002). Also, resting blood pressure and heart rate remained unaffected by either intervention (not presented here).

###### 

Changes in biochemical markers during the study. Values are mean ± SD.

                              Baseline        At 7 days       
  --------------------------- --------------- --------------- -------------------------------------------------
  Insulin (IU/mL)             5.3 ± 1.6       4.6 ± 1.6       4.7 ± 1.5
  Ghrelin (ng/mL)             9.1 ± 4.3       15.7 ± 4.8      13.4 ± 5.0
  IGF-1 (ng/mL)               513.1 ± 235.3   572.5 ± 293.1   464.9 ± 192.2 [\*](#tf1-1){ref-type="table-fn"}
  Creatine kinase (U/L)       214.0 ± 125.8   229.5 ± 125.1   220.4 ± 130.7
  Myoglobin (ng/mL)           36.6 ± 12.8     42.1 ± 15.1     41.3 ± 15.5
  C-reactive protein (mg/L)   1.4 ± 0.8       0.7 ± 0.6       0.4 ± 0.5 [\*](#tf1-1){ref-type="table-fn"}
  Ferritin (μg/L)             31.8 ± 19.7     26.2 ± 22.0     25.4 ± 19.2 [\*](#tf1-1){ref-type="table-fn"}
  ESR (mm/1 h)                4.6 ± 3.0       4.1 ± 2.3       4.4 ± 2.5
  Lactate (mmol/L)            2.0 ± 0.7       1.8 ± 0.4       1.9 ± 0.5

*Abbreviations*: IGF-1 -- insulin-like growth factor 1, ESR -- erythrocyte sedimentation rate.

indicates a significant difference (*P* ≤ 0.05) for time vs. trial interaction between placebo and H~2~ intervention.

![Changes in exercise performance outcomes at baseline vs. follow-up (7 days). Values are presented as mean percentage changes, with error bars representing SD. Asterisk (\*) indicates a significant difference between trials at *P* ≤ 0.05. MVIS -- maximal voluntary isometric strength, VO~2max~ -- maximal oxygen uptake.](JBS-36-88756-g002){#f0002}

![Individual changes in primary treatment outcome (running time-to-exhaustion) between trials.](JBS-36-88756-g003){#f0003}

DISCUSSION {#sec4}
==========

This first-in-humans randomized controlled pilot trial provided preliminary evidence that short-term hydrogen inhalation is superior to placebo (room air) in improving exercise performance in healthy men and women, with ergogenic effects of hydrogen accompanied by notable changes in selected hormonal and inflammatory biomarkers at follow-up. However, inhalational H~2~ demonstrated no significant effect on insulin and ghrelin secretion. In addition, hydrogen inhalation caused no adverse events during our trial, implying low risk of this route of H~2~ administration for a short-term experimental period.

Hydrogen administration as a performance-enhancing intervention in humans dates back to 2012. A Japanese group was first to demonstrate that H~2~ dispensed before exercise during 7 days reduced blood lactate levels and improved the exercise-induced decline of muscle function in male soccer players subjected to strenuous exercise \[[@cit0005]\]. Peak torque and muscle activity throughout 100 repetitions of maximal isokinetic knee extension appear to be less attenuated after hydrogen intervention, as compared to placebo. Similar results were found in a recent study \[[@cit0008]\], with 2-week hydrogen intake maintaining peak power output during repetitive sprints to exhaustion in trained male cyclists. Our study confirmed the above results, with inhalational hydrogen increasing peak running velocity during exhaustive exercise and attenuating the drop in maximal isometric strength of the upper body muscles. Although this level of enhancement for peak running velocity (4.2%) could be considered trivial, it might be relevant for competing athletes, particularly due to the fact that the effects were noted after such short-term administration. A combination of a nominal increase in time-to-exhaustion and notable improvement of maximal running speed after inhaling H~2~ (although VO~2max~ tended to drop at follow-up) perhaps suggests better anaerobic capacity at the end of exercise. Hence, H~2~ inhalation might be a suitable performance-enhancing strategy for sporting activities characterized by a high anaerobic contribution, including middle- and long-distance events, team games or martial arts. While previous studies used magnesium-based hydrogen \[[@cit0018]\], with magnesium possibly contributing to the ergogenic properties of the formulation by itself, the present study confirmed beneficial effects of pure hydrogen gas *per se*.

Although the exact mechanism of H~2~ action remains to be elucidated, the acute ergogenic effects of hydrogen might be due to its strong antioxidative power and buffering capacity that could counterbalance exercise-induced changes in metabolism \[[@cit0019]\]. Furthermore, hydrogen appears to stimulate many signalling pathways and expression of genes that alter mitochondrial bioenergetics and hormone secretion \[[@cit0020],[@cit0021]\], which in turn might have a steady effect on exercise performance. In the present study, we demonstrated an effect of hydrogen on insulin-like growth factor-1, an anabolic hormone that acts as a primary mediator of the effects of growth hormone. Serum IGF-1 appeared to drop by \~ 10% after 7-day hydrogen inhalation while serum IGF-1 remained high after placebo intervention, implying a possible down-regulation link between exogenous H~2~ and the anabolic response. This disagrees with a recent paper that reported an up-regulating effect of hydrogen-rich water on the growth hormone-IGF-1 axis, with an effect mediated by ghrelin, a peptide hormone produced predominantly in the gut \[[@cit0022]\]. We found no notable differences in serum ghrelin response after hydrogen gas or placebo in our pilot trial. This suggests that inhalational and oral hydrogen might have different effects on the ghrelin-growth-hormone-IGF-1 axis, with ghrelin-mediated effects perhaps playing a minor or irrelevant role during short-term hydrogen inhalation. A drop in IGF-1 driven by hydrogen inhalation could be beneficial among athletes, particularly those who strive for lower body mass, since a decreased level of IGF-1 seems to be associated with reduced weight and fat mass in an active population \[[@cit0023]\]. H~2~ inhalation might, therefore, be recognized as a novel short-term strategy to manage weight, yet more studies are needed to confirm this presumption. We also found that H~2~ inhalation reduces levels of serum ferritin and CRP, both non-specific biomarkers of inflammation. This corroborates previous findings from animal and human studies about anti-inflammatory effects of H~2~ \[[@cit0024],[@cit0025]\], with hydrogen gas possibly exerting a regulatory role in the release of pro- and anti-inflammatory cytokines mediated by haem oxygenase-1 expression and activation \[[@cit0026]\]. In the context of the athletic environment, which is often characterized by low-grade systemic inflammation \[[@cit0027]\], inhalational hydrogen thus may contribute to the more favourable internal milieu and perhaps act as a protective compound \[[@cit0028]\] and an alternative to non-steroidal anti-inflammatory agents. On the other hand, regular exercise induces inflammation to promote repair, remodelling and signalling in the body, with this hormetic response considered beneficial to achieve abiding muscle overcompensation and adaptation \[[@cit0029]\]. In the present study, we found that non-specific biomarkers of inflammation were reduced after short-term H~2~ inhalation, yet whether hydrogen affects long-term hormesis remains unknown at the moment. A recent study \[[@cit0030]\] proposed that H~2~ may act as an exercise mimetic and redox adaptogen, potentiating the benefits from regular exercise (accompanied by low-grade inflammation), and reducing the adverse effects of harmful exercise (high-grade inflammation).

Although our pilot study provided early evidence about the beneficial effects of short-term hydrogen inhalation for athletic performance, several limitations must be considered when the study findings are interpreted. We recruited only physically active young healthy volunteers; it remains unknown how breathing H~2~ affects elite and sub-elite athletes or the active population of advanced age. Here, we evaluated both men and women, yet the small sample size limited subgroup analyses that might reveal possible gender-specific effects of gaseous hydrogen. Even though we asked participants to maintain their usual diets and physical activity levels during the study, a lack of strict control of subject compliance with dietary and exercise regime calls into question a possible role of these confounding variables for changes in study outcomes. The short duration of H~2~ treatment perhaps restricted the scope of our trial to acute responses while long-term intervention might reveal alternative or opposing effects of inhalational hydrogen. With a limited number of clinical tests employed, a course of hydrogen action could not be reliably determined. Therefore, more studies are highly warranted to identify the exact mechanism underlying the ergogenic effects of inhalational hydrogen, using randomized-controlled design for long-term and well-powered trials that include advanced physiological, metabolic and genomic profiling. Also, legislative advocacy is needed to address regulatory issues related to this route of H~2~ administration. While the World Anti-Doping Agency forbids the use of specific medical gases (such as argon and xenon) \[[@cit0001]\], it permits the use of inhalational oxygen, while other therapeutic gases (including molecular hydrogen) are currently not controlled.

CONCLUSIONS {#sec5}
===========

In conclusion, breathing 4% gaseous hydrogen for 20 min/day for 7 days resulted in increased peak running velocity and attenuated the drop in maximal isometric strength of trunk muscles in a cohort of healthy, physically active young men and women. This was accompanied by hydrogen-driven changes in serum levels of insulin-like growth hormone-1, ferritin and C-reactive protein at follow-up, as compared to room air inhalation. Inhalational hydrogen should be further evaluated for its efficacy and safety in an athletic environment.
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